Citations

Clear

15 citation(s) found for "Chen, Yong".

Federated target trial emulation for time-to-event outcomes via POLARIS: Pooled-equivalent One-shot Likelihood Aggregation for Real-world Inference in Survival
Wang, Tingyin, Lei, Yuqing , Li, Lu , Wang, Yudong, Wu, Yue, Chen, Siqi, Zhang, Bingyu, Feng, Jingna , Kong, Zifang, Wang, Chengrong, Zhou, Yujia, Amaro, Anastassia , Qiu, Jingmei, Lu, Yuan, Liu, M , Tao, Cui, Xu, Hua, Lu, Yiwen, Chen, Yi , Tang, Huilin , Zhang, Bingyu , Hu, Jie , Wang, Huiyuan, Liu, Yu‐Lun , Chen, Yong

Mayo Clinic

No container title available | May 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9613167/v1 | PMID 42239773 Get It

Abstract Heterogeneous treatment effects (HTE) are key to precision medicine, but most real-world studies lack the scale and diversity needed to detect them. While multi-site analyses offer a potential solution, data-sharing constraints often prevent access to patient-level information across institutions. We introduce POLARIS, a federated framework for time-to-event target trial emulation. POLARIS converts each site’s weighted Cox risk function into a compact tensor shared once with the coordinating center, enabling lossless reproduction of pooled estimates without sharing patient-level data. We applied POLARIS across five U.S. health systems to study risk of gastrointestinal outcomes after GLP-1 receptor agonist (GLP-1RAs) initiation versus sodium-glucose cotransporter 2 inhibitors (SGLT2is) and dipeptidyl peptidase 4 inhibitors (DPP4is). Results showed that GLP-1RAs were consistently associated with higher risks of nausea and vomiting, particularly among men, individuals with higher baseline HbA1c (≥ 8.5%), and lipid therapy. POLARIS provides a scalable solution for distributed target trial emulation and fine-grained assessment of HTE across diverse health systems.
Artificial Intelligence (AI)‐based dynamic predictions of longitudinal and survival data of Alzheimer's disease
Chen, Yong, Tao, Cui, Lundin, Sori Kim , Schulz, Paul Ernest

Mayo Clinic

Alzheimer's & Dementia | December 24, 2025 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_103788 Get It

Abstract Background Dynamically predicting patients at risk of Alzheimer's disease (AD) is crucial for timely treatment and care in precision medicine. Method We present a novel architecture, a Kolmogorov‐Arnold networks (KANs)‐based joint prediction model of longitudinal and survival data (JM‐KAN). Real‐life data of patients with Mild Cognitive Impairment (MCI) with no prior AD diagnosis from National Alzheimer's Coordinating Center (NACC) dataset was utilized for individualized predictions. We built joint models with landmark times every 1 year up to 4 years after the MCI diagnosis, and predicted survival outcomes one year after each landmark (i.e. 1, 2, 3, and 4 years). Integrated AUC (iAUC), and integrated Brier score (iBS) were measured for existing prediction models and our novel architecture. Result Out of 2711 unique patients with MCI, 821 patients progressed to develop AD. Mean time‐to‐event in years was 3.19 (standard deviation (SD): 2.29). The number of visits prior to AD diagnosis was 4.03 (SD: 2.41). With iAUC of 0.789, iBS of 0.118, JM‐KAN has both the highest iAUC and lowest iBS among joint models, which indicates superiority in discrimination and overall performance. For individualized predictions, the model successfully predicted both longitudinal risk factors and survival probability, as new information came in every year. Conclusion Using neural network‐based Artificial Intelligence (AI) model, we demonstrated that this architecture improves upon prior methods in dynamically updating predictions of AD as new longitudinal data becomes available.
Exploring Associations Between COVID-19 Bivalent Vaccines and Their Related Adverse Events: A Correlational Study
Tao, Wei , Sun, Zenan , Chen, Yong , Li, Yiming , Lundin, Sori Kim , Dang, Yifang , Tao, Cui

Mayo Clinic

No container title available | March 10, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6152825/v1 | PMID 40162215 Get It

Abstract Introduction COVID-19, a global health crisis, prompted rapid vaccine development. Bivalent vaccines by Pfizer-BioNTech and Moderna target both original and Omicron strains. Despite vaccination efforts, the persistence of adverse events underscores the importance of ongoing safety monitoring. Method We collected COVID-19 bivalent vaccine adverse event reports from the Vaccine Adverse Event Reporting System (VAERS) (September 15, 2022, to September 1, 2023). The Medical Dictionary for Regulatory Activities (MedDRA) categorized reported symptoms into corresponding concepts. Statistical analyses included zero-truncated Poisson regression for estimating symptom rates, logistic regression for identifying risk factors, and Spearman correlation for assessing non-parametric relationships between adverse events in different System Organ Classes (SOCs). Results Our analysis of COVID-19 bivalent vaccine adverse events identified significant correlations between SOCs. Notably, a positive correlation (ρ = 0.3) linked Infections (SOC 1) with Respiratory disorders (SOC 13), while a negative correlation (ρ=-0.3) connected Investigations (SOC 23) with Injury (SOC 24). Zero-truncated Poisson modeling estimated an average of 6.179 symptoms per individual, varying by age, gender, and vaccine. Gender and age significantly influence reported adverse events associated with COVID-19 bivalent vaccines. Females generally experienced higher odds for most SOCs compared to males, except for cardiac and product-related issues. Older adults showed a higher likelihood of symptoms across various SOCs, while children and adolescents had distinct susceptibility patterns. Additionally, Moderna and Pfizer vaccines were associated with different SOCs, with Moderna linked mainly to immune and skin disorders and Pfizer associated primarily with cardiac and metabolic issues. Conclusion In conclusion, our study aligned self-reported items with widely-accepted medical terminology and rigorously analyzed adverse events following COVID-19 bivalent vaccine using advanced statistical methods. The significant findings provide crucial insights, guiding evidence-based strategies and interventions for vaccine safety.
Anlotinib versus placebo as adjuvant therapy for completely resected high-grade soft tissue sarcomas: Interim results of a phase 2, double-blinded, randomized controlled trial.
Wang, Chunmeng , Hu, Xianglin , Huang, Wending, Zhang, Jianrong , Sun, Zhengwang , Chen, Mo , Zhang, S, Yu, Lin , Sun, Yang-bai , Yang, Lingge , Xu, Yu , Zheng, Biqiang , Fujiwara, Tomohiro , Chen, Yong , Houdek, Matthew T. , Yan, Wangjun

Mayo Clinic

Journal of Clinical Oncology | June 13, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 11562-11562

10.1200/jco.2024.42.16_suppl.11562 Get It

11562 Background: High-grade soft tissue sarcomas (STS) pose a therapeutic challenge due to the high risk of recurrence, even following complete resection. Anlotinib is a multi-targeted tyrosine kinase inhibitor blocking angiogenesis pathways of VEGFR, FGFR, and PDGFR. Given a promising efficacy for treating patients with unresectable advanced STS in previous trials, we evaluated the role of anlotinib as adjuvant therapy for completely resected high-grade STS. Methods: In a single-center, double-blinded, randomized, controlled trial, eligible patients were those adults who had not received adjuvant chemotherapy regimens after complete resection of high-grade STS. Patients were randomly assigned in a 1:1 ratio to receive either oral 12 mg anlotinib or placebo once daily on days 1-14 every 3 weeks as a cycle, with up to six cycles until disease recurrence, unmanageable toxicity or death. The primary endpoints included 1-year, 2-year disease-free survival (DFS). Results: Between June 2019 and November 2023, 88 patients were randomly assigned to receive anlotinib (n=44) or placebo (n=44). With a median follow-up of 25.99 months at data accrual cutoff on Jan 15, 2024, the 1-year and 2-year DFS rates were 88% and 77% in the anlotinib group, compared to 64% and 58% in the placebo group. Compared to patients in the placebo group, patients in the anlotinib group had a reduced risk of disease recurrence (HR 0.47 [95% CI 0.22~1.00, P= 0.0445]). The median DFS was not reached. Based on tumor histology, the greatest improvement in DFS with anlotinib versus placebo was observed in patients with myxofibrosarcoma (1-year DFS rate: 82% versus 61%; 2-year DFS rate: 64% versus 43%, HR 0.54 [95% CI 0.17~1.65], P= 0.2698) and undifferentiated pleomorphic sarcoma (1-year DFS rate: 86% versus 67%; 2-year DFS rate: 78% versus 67%, HR 0.58 [95% CI 0.12~2.87], P= 0.4971). Thirty-eight patients experienced adverse events (AEs; 34 with grade 1~2, 4 with grade 3): 28 patients (64%) in the anlotinib group versus 10 patients (23%) in the placebo group ( P<0.001). Three patients discontinued anlotinib, including two for proteinuria/hematuresis (2/44, 5%) and one for secondary poor surgical wound healing (1/44, 2%). Conclusions: Current results suggest anlotinib could lower disease recurrence risk in patients with completely resected high-grade STS, with an acceptable toxicity profile. Clinical trial information: NCT03951571 . [Table: see text]
Unpacking adverse events and associations post COVID-19 vaccination: a deep dive into vaccine adverse event reporting system data
Lundin, Sori Kim , Li, Jianfu , Tao, Wei , Chen, Yong , Li, Yiming , Dang, Yifang , Tao, Cui

Mayo Clinic

Expert Review of Vaccines | December 8, 2023 | Volume: 23 | Issue: 1 | Pages: 53-59

10.1080/14760584.2023.2292203 | PMID 38063069 Get It

Prediction of post‐vaccination Guillain‐Barré syndrome using data from a passive surveillance system
Luo, Chongliang , Jiang, Ying , Du, Jingcheng , Re, Vincent Lo , Ellenberg, Susan S. , Tao, Cui , Chen, Yong , Tao, Cui , Tong, Jiayi , Huang, Jing Yang , Poland, Gregory A.

Mayo Clinic

Pharmacoepidemiology and Drug Safety | February 5, 2021 | Volume: 30 | Issue: 5 | Pages: 602-609

10.1002/pds.5196 | PMID 33533072 Get It

AbstractPurposeSevere adverse events (AEs), such as Guillain‐Barré syndrome (GBS) occur rarely after influenza vaccination. We identify highly associated AEs with GBS and develop prediction models for GBS using the US Vaccine Adverse Event Reporting System (VAERS) reports following trivalent influenza vaccination (FLU3).MethodsThis study analyzed 80 059 reports from the US VAERS between 1990 and 2017. Several AEs were identified as highly associated with GBS and were used to develop the prediction model. Some common and mild AEs that were suspected to be underreported when GBS occurred simultaneously were removed from the final model. The analyses were validated using European influenza vaccine AEs data from EudraVigilance.ResultsOf the 80 059 reports, 1185 (1.5%) were annotated as GBS related. Twenty‐four AEs were identified as having strong association with GBS. The full prediction model, using age, sex, and all 24 AEs achieved an area under the receiver operating characteristic (ROC) curve (AUC) of 85.4% (90% CI: [83.8%, 86.9%]). After excluding the nine (e.g., pruritus, rash, injection site pain) likely underreported AEs, the final AUC became 77.5% (90% CI: [75.5%, 79.6%]). Two hundred and one (0.25%) reports were predicted as of high risk of GBS (predicted probability >25%) and 84 actually developed GBS.ConclusionThe prediction performance demonstrated the potential of developing risk‐prediction models utilizing the VAERS cohort. Excluding the likely underreported AEs sacrificed some prediction power but made the model more interpretable and feasible. The high absolute risk of even a small number of AE combinations suggests the promise of GBS prediction within the VAERS dataset.
Use of Deep Learning to Analyze Social Media Discussions About the Human Papillomavirus Vaccine
Du, Jingcheng , Luo, Chongliang , Bian, Jiang , Cunningham, Rachel , Boom, Julie A. , Chen, Yong , Tao, Cui , Tao, Cui , Bian, Jiang , Shegog, Ross , Poland, Gregory A.

Mayo Clinic

JAMA Network Open | November 13, 2020 | Volume: 3 | Issue: 11 | Pages: e2022025

10.1001/jamanetworkopen.2020.22025 | PMID 33185676 Get It

Comparative Analysis of Acral Melanoma in Chinese and Caucasian Patients
Huang, Kai , Gabriel, Emmanuel , Misra, Subhasis , Chen, Yong , Asadi, Arash Kimyai, Chen, Yong , Gabriel, Emmanuel M , Xu, Yu , Bagaria, Sanjay P.

Mayo Clinic

Journal of Skin Cancer | October 7, 2020 | Volume: 2020 | Issue: No issue available | Pages: 1-8

10.1155/2020/5169051 | PMID 33083061 Get It

Background. Acral melanoma (AM) is a rare subtype of melanoma, which is one of the least common in Caucasian patients but is a common subtype of melanoma in Chinese patients. It is unclear if prognosis differs between Chinese and Caucasian patients diagnosed with AM. The aim of our study is to investigate patient characteristics and survival differences between Chinese and Caucasian AM patients. Methods. Two large institutional melanoma databases from Fudan University Shanghai Cancer Center (FUSCC) and Mayo Clinic enterprise were retrospectively reviewed from 2009 to 2015. Clinicopathologic and survival data were collected and analyzed between the two groups. The primary outcome was disease-specific survival (DSS) and was calculated using the Kaplan Meier (KM) method. Results. The Chinese group presented with more advanced disease compared with Caucasians: thicker Breslow depth (median 3.0 mm vs. 1.2 mm, p = 0.003 ), more ulcerated disease (66.1% vs. 29%; p < 0.001 ), and advanced stages (stage II/III 84.3% vs. 37.1%; p < 0.001 ). No significant difference was identified in terms of age at diagnosis, location, histologic subtypes, or node positive rate. The 5-year DSS rate was 68.4% and 73% ( p = 0.56 ) in Chinese and Caucasians AM patients, respectively. Male gender, Breslow thickness, ulceration, and positive sentinel lymph nodes were independent poor prognostic factors on multivariate analysis. Conclusions. There appears to be no difference in stage-stratified survival between Chinese and Caucasians, supporting the implementation of clinical trials for AM that could include both Chinese and Caucasian patients.
Completion lymph node dissection in patients with sentinel lymph node positive cutaneous head and neck melanoma
Huang, Kai , Misra, Subhasis , Lemini, Riccardo , Chen, Yong , Speicher, Leigh L. , Dawson, Nancy L. , Tolaymat, Leila , Bagaria, Sanjay P. , Gabriel, Emmanuel , Tolaymat, Leila M, Gabriel, Emmanuel M , Bagaria, Sanjay P

Mayo Clinic

Journal of Surgical Oncology | July 12, 2020 | Volume: 122 | Issue: 6 | Pages: 1057-1065

10.1002/jso.26119 | PMID 32654173 Get It

AbstractBackgroundRelatively few cutaneous head and neck melanoma (CHNM) patients with were included in the multicenter selective lymphadenectomy trial II (MSLT‐II). Our objective was to investigate whether immediate completion lymph node dissection completion of lymph node dissection (CLND) was associated with survival benefit for sentinel lymph node (SLN) positive CHNM using the National Cancer Database.MethodsSLN positive patients with CHNM from 2012 to 2014 were retrospectively analyzed. Patients were divided into two groups: those who underwent SLN biopsy (SLNB) only versus those who underwent SLNB followed by CLND (SLNB + CLND). The primary outcome was 5‐year overall survival (OS).ResultsAmong 530 SLNB + patients, 342 patients underwent SLNB followed by CLND (SLNB + CLND). The SLNB only group had fewer positive SLN, less advanced pathologic stage, and a lower rate of adjuvant immunotherapy. There was no significant difference in 5‐year OS between the two groups (51.0% vs 67%; P = .56). After adjusting for pathologic stage, there remained no difference in 5‐year OS among patients with stage IIIA (63.0% vs. 73.6%, P = 0.22) or IIIB/IIIC disease (39.1% vs 57.8%; P = .52).ConclusionsUsing a large nationwide database, CLND was not shown to be associated with improved OS for patients with SLNB positive CHNM, validating the results of MSLT‐II.
Comparative Analysis of Acral Melanoma in Chinese and Caucasian Patients
Misra, Subhasis, Chen, Yong , Huang, Kai , Xu, Yü , Gabriel, Emmanuel , Chen, Yong , Bagaria, Sanjay P.

Mayo Clinic

No container title available | February 6, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.2.22789/v1 Get It

Abstract Background Acral melanoma is the most common subtype of melanoma in Chinese patients and one of the least common in Caucasian patients. It has been unclear if outcomes differ between Chinese and Caucasian patients diagnosed with Acral Melanoma. This study investigated patient characteristics and survival differences between Chinese and Caucasian Acral Melanoma patients. Methods Two large institutional melanoma databases from Fudan University Shanghai Cancer Center (FUSCC) and Mayo Clinic enterprise, were retrospectively reviewed from 2009 to 2015. Clinicopathologic and survival data were collected and analyzed between the two groups. The primary outcome was disease-specific survival (DSS) and was calculated using the Kaplan Meier (KM) method. Results The Chinese group presented with more advanced disease compared with Caucasians: thicker Breslow depth (median 3.0 mm vs. 1.2 mm, p=0.003), more ulcerated disease (66.1% vs 29%; p<0.001), and advanced stages (stage II/III 84.3% vs. 37.1%; p<0.001). No significant difference was identified in terms of age at diagnosis, location, histologic subtypes, or node positive rate. The 5-year DSS rate was 68.4% and 73% (p=0.56) for Chinese and Caucasians, respectively. Male gender, Breslow thickness, ulceration, and positive sentinel lymph nodes predicted worse DSS on multivariate Cox regression analysis. Conclusions There appears to be no difference in stage-stratified survival between Chinese and Caucasians, supporting the implementation of clinical trials of AM that could include both Chinese and Caucasian patients.